Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00616772 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood
A Phase 3 study of Coronary Artery Disease and Dyslipidemia, sponsored by AbbVie (prior sponsor, Abbott).
- Completed
- Registry status
- Phase 3
- Development phase
- 682
- Enrollment target
- 20
- Study locations
NCT00616772 is a Phase 3 study of Coronary Artery Disease and Dyslipidemia that has completed, run by AbbVie (prior sponsor, Abbott). The registered enrollment target is 682 participants, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (47% lower). The trial reports 20 study locations across 3 states.
The verdict
NCT00616772, a Phase 3 study of Coronary Artery Disease and Dyslipidemia, has completed, sponsored by AbbVie (prior sponsor, Abbott).
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 682 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after taking atorvastatin.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABT-335
- OTHER Atorvastatin
Study Locations (20)
California
- Site Reference ID/Investigator# 25082 - Anaheim
- Site Reference ID/Investigator# 21347 - Corona
- Site Reference ID/Investigator# 21483 - Garden Grove
- Site Reference ID/Investigator# 21351 - Huntington Beach
- Site Reference ID/Investigator# 21346 - Laguna Hills
- Site Reference ID/Investigator# 21341 - Long Beach
- Site Reference ID/Investigator# 21342 - Norwalk
- Site Reference ID/Investigator# 21321 - Santa Ana
- Site Reference ID/Investigator# 26242 - Tustin
Arizona
- Site Reference ID/Investigator# 6747 - Chandler
- Site Reference ID/Investigator# 7089 - Gilbert
- Site Reference ID/Investigator# 7097 - Mesa
- Site Reference ID/Investigator# 26394 - Phoenix
- Site Reference ID/Investigator# 6848 - Scottsdale
- Site Reference ID/Investigator# 7059 - Tempe
- Site Reference ID/Investigator# 7094 - Tempe
- Site Reference ID/Investigator# 7098 - Tempe
Colorado
- Site Reference ID/Investigator# 15283 - Arvada
- Site Reference ID/Investigator# 7085 - Aurora
- Site Reference ID/Investigator# 6749 - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 682 participants |
| Start Date | 2008-02 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00616772
The ClinicalTrials.gov registry entry for NCT00616772 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 682 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,284-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (47% lower). The listed sponsor is AbbVie (prior sponsor, Abbott), which has 88 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00616772 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT00616772 about?
NCT00616772 is a clinical study titled "Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the Blood". The primary purpose of this study is to test the effect and safety of once daily ABT-335 on the thickness of the lining of the carotid artery (a blood vessel to the brain) in patients with abnormal blood lipids who have optimal levels of low density lipoprotein cholesterol ("bad cholesterol") after ...
What is the current status of trial NCT00616772?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 682 participants. The study started on 2008-02. Estimated completion is 2012-09.
What conditions does trial NCT00616772 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Dyslipidemia, Coronary Heart Disease.
What interventions are being tested in trial NCT00616772?
The interventions under investigation include: Placebo (DRUG), ABT-335 (DRUG), Atorvastatin (OTHER).
Who is sponsoring clinical trial NCT00616772?
This trial is sponsored by AbbVie (prior sponsor, Abbott), which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00616772 being conducted?
This trial has 20 study locations across Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque
RECRUITING · Phase 3
-
RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women
RECRUITING · Phase 3
-
REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities
RECRUITING · Phase 3
-
PANDORA: Delirium Prevention After Cardiac Surgery Using IV Acetaminophen to Prevent Postoperative Delirium in Older Cardiac Surgical Patients
ACTIVE NOT RECRUITING · Phase 3
-
Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Addition to Maximally Tolerated Statin Therapy on Atherosclerotic Plaque Progression in Participants With a Diagnosis of Non-obstructive Coronary Artery Disease Without Previous Cardiovascular Events
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.